Pharmaceutical

BioAge secures $170m for obesity therapeutics development

BioAge Labs has secured $170m in an Series D funding round to progress the development of therapeutics for obesity and metabolic diseases.

Feb 14, 2024 - 18:00
BioAge secures $170m for obesity therapeutics development
BioAge Labs has secured $170m in an Series D funding round to progress the development of therapeutics for obesity and metabolic diseases.
Read the original article

Tags:

Previous Article

FDA grants fast track status to Edgewise’s Duchenne treatment

Next Article

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval

PF-07960613 by Pfizer for Respiratory Syncytial Virus (...

Jun 14, 2024

Amphastar Pharmaceuticals gets grant for medication container assembly with cap and hold down members

Amphastar Pharmaceuticals gets grant for medication con...

Jun 12, 2024

Novo Nordisk’s ocedurenone Phase III flop costs company $816m

Novo Nordisk’s ocedurenone Phase III flop costs company...

Jun 28, 2024